Market rally led by large caps; better value in smaller stocks
The local market surged to record highs in the September quarter of 2024, with the S&P/ASX 200 benchmark closing at 8,270, up 6% in three months. On an unweighted average, our coverage trades at a 6% premium to our fair value estimates. We consider this modestly overvalued, a touch above the 10-year average price/fair value of 1.04. 

Read more in our report today.

Key highlights of the report include:

  • Market and economic outlook for AU & NZ
  • Key challenges in Q4 2024
  • Market valuation overview
  • Top stock picks by sector for Q4 2024


Receive your copy:
Submit your details here to receive the report, we may be in touch with you to discuss your requirements if requested.



By clicking Submit, you agree to Morningstar's Privacy Policy
 
© Copyright 2024 Morningstar Inc.  |  Privacy Policy  |   Legal Notices   |  Regulatory Disclosures  |  Global Contacts  

Disclaimer: Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared without reference to your financial objectives, situation or needs. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest.

Morningstar Australasia Pty Limited (MAPL) (ABN 95 090 665 544, AFS Licence 240892) and/or Morningstar Research Ltd, are subsidiaries of Morningstar, Inc., a leading provider of independent investment research in North America, Europe, Australia, and Asia. For more information refer to the MAPL Financial Services Guide (AU). Morningstar Investment Management Australia Limited (MIMAL) (ABN 54 071 808 501, AFS Licence 22896) is the Responsible Entity and issuer of the Morningstar Investment Funds. For more information refer to the MIMAL Financial Services Guide.

MAPL and MRL avoid conflicts of interest by not undertaking or publishing qualitative analyst research on MIMAL’s investment products.